FDA approves nuclear output inhibitor XPOVIOTM (selinexor) in combination with low-dose dexamethasone for the treatment of RRMM

recently, dekiPharmaceutical(http://and partner KaryopTherapeutics Inc(NASDAQ: KPTI) announced that the U.SFood andDrug(http://Administration (
FDA(http://) has officially approved the development of the world's first nuclear output inhibitor XIOPOVTM (selinexor, deki pharmaceuticalhttp:// products)Codenamed ATG-010) is combined with low-dose dexamethasone for the treatment of recurrent refractory multiple myeloma (RRMM)these patients received at least a multi-line treatment that included protease inhibitors, immunomodulators, and CD38 monoclonal antibodiesin addition, a phase III clinical trial
trial (http:// (BOSTON) for evaluating selinexor in combination with boronitomi and low-dose dexamethasone for the treatment of recurrent and refractory multiple myeloma has been completed The FDA's accelerated approval provides a new drug (http:// for patients with recurrent multiple myeloma who have a completely different mechanism than existing clinical drugs 　　About XPOVIOTM (selinexor) XPOVIOTM is a world-first, oral, selective nuclear output inhibitor (SINE) that binds and inhibits the function of the nuclear output protein XPO1 (also known as CRM1), causing tumor suppressor saccumulation in the nucleus, thereby restarting and amplifying its function as a tumor inhibitor, causing the apoptosis of cancer cells and largely protecting normal cells from damage XPOVIOTM has also submitted a European Marketing Authorization Application (MAA) to the European Medicines (http:// Administration (MAA) in addition to the treatment of boronitomi, caifgeami, Rhatomide, Parmadomide and daratumab for the failure of the treatment of recurrent multiple myeloma indications in July 2019 At the same time, selinexor is also conducting clinical studies on recurrent or difficult to treat diffuse large B-cell lymphoma (DLBCL) indications On May 29, 2018, Deqi Pharmaceuticals and Karyopharm signed a strategic cooperation agreement in Shanghai to jointly develop four innovative oral medicines in clinical development, including ATG-010 (XGPOVIOTM, selinexor) After the launch of the partnership, ATG-010 received clinical approval from China's State Drug Administration on January 28, 2019, and will begin clinical trials in August this year it is reported that in addition to continuing to promote atG-010 in the development of related indications beyond multiple myeloma, Deqi Pharmaceuticals is forming a commercial team to actively prepare selinexor and subsequent products to market